Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of lemzoparlimab plus budigalimab versus chemotherapy in metastatic urothelial carcinoma after prior checkpoint inhibitor therapy
MOH_2024-10-06_013680Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of budigalimab and livmoniplimab in transitional cell carcinoma (TCC) and transitional cell carcinoma of the bladder (TCC) (3 arms), sponsored by AbbVie Inc. Started Oct 2024; status: completed.
02
Drugs
budigalimablivmoniplimab
03
Conditions
transitional cell carcinoma (TCC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on MOH_2024-10-06_013680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-10-06_013680.